February 19, 2025 12:07 pm
A global investment firm focuses on private venture and growth assets. The firm manages over USD 2 billion and invests in highly innovative and disruptive companies in the biotechnology, enterprise-facing core technology, and consumer sectors. The firm is open to global companies in Pre-Seed to Series B rounds and prefers to lead its investments. The firm is capable of investing up to $25M USD.
Within life sciences, the firm invests in therapeutics and med-techs with strong preference in aging-related indications including, but not limited to, oncology, immunology, neurology, ophthalmology, cardiovascular, liver, and kidney diseases. The firm typically avoids rare diseases as the firm emphasizes breakthrough technologies. The firm is open to company being as early as discovery stages.
The firm prefers to take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Posted by Next Phase Admin
Categories: Hot Mandates
Tags:
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.